Bronchitis Market Size was valued at USD 13.23 Billion in 2023. The Global Bronchitis industry is projected to grow from USD 14.83 Billion in 2024 to USD 22.63 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.43% during the forecast period (2024 - 2032).Bronchitis is an inflammation of the bronchial tubes, which transport air to and from the lungs. Bronchitis patients frequently cough up heavy mucus. Bronchitis can be acute or persistent.
Acute Bronchitis, usually known as a chest cold, is frequently caused by a cough and cold and normally resolves within a week to ten days with no long-term consequences, but the cough may persist for a few weeks. Chronic Bronchitis is becoming more common with age, cigarette use, occupational exposure, and socioeconomic position. Other factors influencing the market for bronchitis include a growth in the senior population, which has a higher prevalence of Bronchitis, an increase in smoking habits, which may be involuntary passive inhalation, and rising levels of inhaling hazardous chemical pollutants. Thus, all these factors are anticipated to drive the market of bronchitis over the forecast period.
Viatris Inc., a healthcare company, has jointly announced with Kindeva Drug Delivery, LP that it will be releasing budesonide and formoterol fumarate dihydrate inhalation aerosol after Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA). It’s the first generic drug version of AstraZeneca’s Symbicort®. Breyna is made up of drugs plus devices for patients suffering from asthma or chronic obstructive pulmonary disease (COPD), who can acquire either 80 mcg/4.5 mcg or 160 mcg/4.5 mcg dose strengths as obtainable immediately. The asthmatic age group starts at six years old and above, while emphysema and chronic bronchitis among other patients with COPD may count themselves among its beneficiaries.
The Miles Government launched its free Respiratory Syncytial Virus immunization program in April 2024. This $31 million immunization program was rolled out before the winter season around 2024 to protect newborn babies, eligible infants, and young children from having serious illnesses due to RSVs. For Queensland’s newborns, this is the first group to get such shots for free. Monoclonal antibody product nirsevimab, which was approved by the Therapeutic Goods Administration (TGA), has now reached all public and private birthing hospitals across Queensland. The Royal Brisbane Women's Hospital has become one of the initial health facilities where newborns can be vaccinated against RSV, starting later this month at other birthing facilities.
Generium JSC has confirmed that its biosimilar for omalizumab, Genolar®, is now commercially available in Russia for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria since February 2022. It adds up to Generium’s third biosimilar generated utilizing the Selexis SUREtechnology Platform® and commercialized worldwide. The Genolar biosimilar is a recombinant humanized IgG1k mAb that binds to free human IgE. Genolar is used in improving moderate to severe persistent asthma control caused by allergy, symptoms of which are not sufficiently controlled by inhalation glucocorticosteroids patients aged six years and older.
COVID-19 Impact Analysis
As a result of the COVID-19 pandemic, most healthcare, pharmaceutical, and biotechnology businesses have focused on diagnostic kits, safety equipment (PPE kits, face shields, masks), and treatments and medication against the Novel coronavirus. R&D laboratories are also working to develop a novel vaccination against Novel coronavirus. Furthermore, medical personnel delivers COVID-19-related services, resulting in neglect in other healthcare areas. Persons suffering from Bronchitis must take additional measures because bronchitis is one of the illnesses mentioned under COPD and has a significant risk of becoming infected with new coronaviruses, making the situation worse. Bronchitis does not produce COVID-19, but a patient with chronic Bronchitis would be exceedingly unwell if infected with a new coronavirus, which might result in death. As a result, persons suffering from lung ailments such as bronchitis are advised to stay at home, and additional treatment is provided through virtual clinics.
A huge patient pool is a crucial element driving the growth of the market for bronchitis during the forecast period. In addition, harmful habits, such as smoking and growing levels of chemical pollutants, are important drivers driving market expansion. The rising prevalence of chronic bronchitis is linked to age, cigarette use, occupational exposure, and socioeconomic position. Other factors influencing the bronchitis treatment market include an increase in the geriatric population, which has an increased prevalence of bronchitis, an increase in smoking habits, which may be involuntary passive inhalation, and increased levels of breathing toxic chemical pollutants. Furthermore, a sedentary lifestyle and the availability of improved bronchitis therapy drive the market for bronchitis growth.
Market Drivers
The increasing prevalence of lung diseases is a major factor driving the market for bronchitis leiomyoma growth in the coming years. Chronic respiratory disorders are among the most frequent noncommunicable diseases worldwide, owing to the prevalence of noxious environmental, occupational, and behavioral inhalational exposures. In addition to chronic obstructive pulmonary disease (COPD) and asthma, chronic respiratory illnesses include interstitial lung disease, pulmonary sarcoidosis, and pneumoconioses such as silicosis and asbestosis.
Market Restraints:
Lack of patient knowledge about the condition and distinct symptoms may limit the market for bronchitis growth throughout the projected period. However, stringent rules governing medication release and the cost of approval are expected to impede the market for bronchitis growth.
Market Opportunities:
Cigarette smoking is the leading cause of chronic bronchitis. More than 90% of patients with chronic bronchitis have a smoking history, even though only 15% of all cigarette smokers are eventually diagnosed with some form of COPD, such as chronic bronchitis. Smoking habit is continually increasing among the young population worldwide, and bronchitis is one of the negative results of smoking. For instance, smoking killed almost 8 million people in 2021, and the number of smokers rose as young people worldwide picked up the habit. This increased smoking habit will create an opportunity for drug manufacturers during the forecast period.
The market of bronchitis is segmented based on type into acute bronchitis and chronic bronchitis. The chronic bronchitis segment held a significant revenue share in the bronchitis market growth in 2021. Chronic bronchitis is a dangerous medical illness characterized by long-term inflammation of the bronchi of the lungs. Persistent bronchitis is a chronic productive cough lasting more than three months that occur within two years. It's one of the numerous lung illnesses with a significant morbidity and fatality rate. Chronic bronchitis is often characterized by repeated lung inflammation and damage. It is closely related to Smoking and one of its causes.
The market of bronchitis is segmented based on treatment into drugs and oxygen therapy. The drugs segment accounted for the majority of revenue share in the market in 2021. This growth is majorly attributed to the growing usage of drugs in treating bronchitis and rising product approvals from the regulatory authority. The oxygen therapy segment is expected to register a significant CAGR over the forecast period due to reducing the oxygen level in the patient bronchitis as it directly impacts the lungs. The rising cases of chronic lung disease are responsible for the segment’s growth during the forecast period.
The market of bronchitis is segmented based on the diagnosis into chest X-rays, sputum tests, and pulmonary function tests. The chest x-ray segment held a significant revenue share in the market in 2021. Chronic lung diseases are initially diagnosed with chest X-rays in hospitals and private laboratories. As a result, it drives the demand for chest X-rays for diagnosis, which in turn fuels the growth of the segment in the market.
Global Bronchitis Market Share, By Region, 2021 (%)
By Region, the bronchitis market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the market with the largest revenue share in 2021. Asia-Pacific is to register a significant growth rate over the forecast period.
North America
North America held most of the revenue share in the market for bronchitis in 2021. This is primarily attributed to factors such as the increasing incidence of Bronchitis, a rising smoking habit in the young generation, and a growing number of strategic initiatives by industry players across the Region. For instance, in February 2022, the Centers for Disease Control and Prevention (CDC) released a report which showed that 5% of adults in the United States were diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, or chronic emphysema. As a result, it drives the demand for bronchitis treatment in the country, propelling the market growth in this Region.
Asia-Pacific
Asia-Pacific is expected to grow at a significant CAGR over the coming years for the market for bronchitis due to the increased prevalence of COPD, asthma, and other lung diseases and increasing initiatives by the government and pharmaceutical organizations to spread awareness. This growth can be ascribed to the rising trend of Smoking among the young generation, the rising incidence of chronic illness, the Region's expanding senior population, an increase in air pollution, and an increase in healthcare spending and facilities.
Bronchitis Market Competitive Landscape
The market includes tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach with diverse product portfolios. Companies such as GlaxoSmithKline Pharmaceuticals Limited and Boehringer Ingelheim dominate the market for bronchitis due to product differentiation, financial stability, strategic developments, and diversified regional presence. The participants are focused on research and development. Furthermore, they support strategic growth efforts like product development, product launch, joint ventures, and partnerships to increase their market position and grab a large consumer base.
Key Players:
Prominent players in the market reseaerch of bronchitis include
Objectives of the Study
The objectives of the study are summarized in 5 stages. They are as mentioned below:
Bronchitis Market Forecast and Size:
To identify and estimate the market size of bronchitis segmented by type, treatment, diagnosis, and value (in U.S. dollars). Also, to understand the consumption/ demand created by consumers in the market forecast between 2020 and 2030
Market Trends and Landscape
To identify and infer the drivers, restraints, opportunities, and challenges for the market growth of bronchitis.
Market Influencing Factors:
To find out the factors which are affecting the bronchitis market size among consumers
Impact of COVID-19:
To identify and understand the various factors involved in the market affected by the pandemic
Company Profiling:
To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company's past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 22.63 Billion |
| CAGR | 7.43% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, Diagnosis |
| Geographies Covered | North America, Europe, Asia-Pacific, and the Rest of the World (RoW) |
| Key Vendors | GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others |
| Key Market Opportunities | Rising smoking habits across the globe |
| Key Market Drivers | Rising prevalence of lung diseases |
Bronchitis Market Highlights:
Frequently Asked Questions (FAQ) :
The bronchitis market forecast period is 2024-2032
The market is expected to register a CAGR of 7.43% over the next ten years, according to bronchitis market research.
The increasing prevalence of lung diseases is the major driver for the Bronchitis Market.
North merica held the largest share in 2021
The major companies operating in the market include GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy's Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
